Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Sailaja, Kagita"'
Publikováno v:
Asian Pacific Journal of Cancer Biology, Vol 6, Iss 1, Pp 27-36 (2021)
Introduction: We aimed to investigate the possible role of antioxidant enzyme polymorphisms CAT -21A/T (rs7943316), CAT -262C/T (rs1001179), GPX1 -198C/T (rs1050450), MPO -463G/A (rs2333227), GSTM1 (rs366631) & GSTT1 (rs17856199) with susceptibility
Externí odkaz:
https://doaj.org/article/96d4f52d7087454997ecb532bec96b5f
Publikováno v:
Indian Journal of Medical and Paediatric Oncology. 39:165-171
Objectives: BCR-ABL1 fusion transcripts with contrasting data on response to imatinib therapy have been reported from different parts of the world. Hence, the present study aimed to determine the frequencies of transcripts and their association with
Publikováno v:
Journal of Pharmacology and Pharmacotherapeutics. 11:28-29
The use of chemotherapy is often limited by toxic side-effects caused to healthy cells. In general, most chemotherapy treatments cause DNA damage or stop cells in mitosis, targeting both cancer and healthy cells. Life-threatening toxicities of chemot
Significance of ATM Gene Polymorphisms in Chronic Myeloid Leukemia - a Case Control Study from India
Autor:
Manjula Gorre, Nageswara Rao Dunna, Sailaja Kagita, Santhoshirani Nanchari, Sarika Jarjapu, Sugunakar Vuree, Phanni Bhushann Meka, Anuradha Cingeetham, Raghunadharao Digumarti, Sandhya Annamaneni, Vishnupriya Satti, Prajitha Edathara Mohandas
Publikováno v:
Asian Pacific Journal of Cancer Prevention. 17:815-821
Background Development of chronic myeloid leukemia (CML) involves formation of double strand breaks (DSBs) which are initially sensed by the ataxia telangiectasia mutated (ATM) signal kinase to induce a DNA damage response (DDR). Mutations or single
Autor:
Vishnupriya Satti, Anuradha Cingeetham, Sailaja Kagita, Raghunadharao Digumarti, Manjula Gorre, Prajitha Mohandas Edathara, Sandhya Annamaneni
Publikováno v:
Gene: X, Vol 1, Iss, Pp-(2019)
Gene: X
Gene: X
Introduction Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder, characterized by the overproduction of myeloid cells in all stages of maturation. It is usually defined by three sequential stages (Chronic, Accelerated and Blast-crisis) w
Autor:
Santhoshi Rani Nanchari, Sugunakar Vuree, Anuradha Cingeetham, Manjula Gorre, Prajitha Mohandas Edathara, Vishnupriya Satti, Sandhya Annamaneni, Raghunadha Rao Digumarthi, Sailaja Kagita, Phanni Bhushann Meka
Publikováno v:
Tumor Biology. 37:5475-5484
Chronic myeloid leukemia (CML) is a monoclonal myeloproliferative disorder of hematopoietic stem cells (HSCs), characterized by reciprocal translocation, leading to the formation of BCR-ABL oncogene with constitutive tyrosine kinase (TK) activity. Th
Publikováno v:
Japanese Journal of Clinical Oncology. 45:749-754
Objective: Altered differentiation is a common feature of haematopoietic malignancies with poor prognosis. CAAT/enhancer binding protein alpha (C/EBPα) is a key transcription factor that regulates myeloid differentiation. This study is aimed to know
Autor:
Srihari Uppalapati, Sangeeta Jiwtani, Raghunadharao Digumarti, Sailaja Kagita, Vijay Gandhi Linga, S. Gundeti
Publikováno v:
Tumor Biology. 35:4443-4446
Imatinib is the frontline therapy for chronic myeloid leukemia (CML) management. Most of the CML patients achieve major responses, but a proportion (nearly 25-35%) of them develop drug resistance. Molecular monitoring using quantitative real-time PCR
Autor:
Anuradha Cingeetham, Raghunadharao Digumarti, Manjula Gorre, Sangeeta Jiwatani, Sudha Sinha, Vishnupriya Satti, Sandhya Annamaneni, Sailaja Kagita, Phanni Bhushann Meka, Nageswara Rao Dunna, Sugunakar Vuree
Publikováno v:
Asian Pacific journal of cancer prevention : APJCP. 16(7)
The human homologue of the mouse double minute 2 (MDM2) gene is a negative regulator of Tp53. MDM2-309TG a functional promoter polymorphism was found to be associated with overexpression thereby attenuation of Tp53 stress response and increased cance
Autor:
Narayana Nagesh, Vijay Gandhi Linga, Sangeeta Jiwatani, S. Gundeti, Srihari Uppalapati, Sailaja Kagita, Raghunadharao Digumarti
Publikováno v:
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 35(7)
Mutations in the Bcr-Abl kinase domain (KD) are a major cause for acquired resistance to imatinib (IM) treatment and have been associated with progression and poor prognosis in chronic myeloid leukemia patients. The present study includes 63 patients